The Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular death (CV), hospitalization for heart failure (HF), and urgent HF visit in adults with HF regardless of left ventricular ejection fraction (LVEF) status. Previously, the sodium-glucose cotransporter 2 (SGLT2) inhibitor had only been approved for HF patients with reduced ejection fraction (HFrEF).

The approval was based on data from the phase 3 DELIVER trial ( Identifier: NCT03619213), a placebo-controlled, event-driven study that included 6263 patients 40 years of age and older with HF and LVEF of greater than 40%, with or without type 2 diabetes. Patients were randomly assigned 1:1 to receive dapagliflozin 10 mg or placebo once daily, in addition to background therapy.

The primary composite endpoint was the time to first occurrence of CV death, hospitalization for HF or an urgent HF visit, in the full study population, as well as in patients with LVEF of less than 60%.

Continue Reading

Over a median follow-up of 2.3 years, treatment with dapagliflozin reduced the composite outcome of CV death or worsening of HF by 18% compared with placebo (hazard ratio [HR], 0.82; 95% CI, 0.73-0.92; <.001). Worsening HF occurred in 11.8% (n=368) of patients in the dapagliflozin arm and 14.5% (n=455) of patients in the placebo arm (HR, 0.79; 95% CI, 0.69-0.91); CV death occurred in 7.4% (n=231) of patients in the dapagliflozin arm and 8.3% (n=261) of patients in the placebo arm (HR, 0.88; 95% CI, 0.74-1.05). The findings were consistent among patients with LVEF of less than 60%, as well as among those with or without diabetes.

Additionally, a pooled analysis of data from the phase 3 DAPA-HF ( Identifier: NCT03036124) and DELIVER trials showed a significant reduction in CV death among HF patients treated with dapagliflozin, compared with placebo, irrespective of LVEF. Over a median follow-up of 22 months, dapagliflozin reduced the risk of CV death by 14% (HR, 0.86; 95% CI, 0.76-0.97; P =.01), death from any cause by 10% (HR, 0.90; 95% CI, 0.82-0.99; P =.03), total (first and repeat) hospitalization for HF by 29% (HR, 0.71; 95% CI, 0.65-0.78; P <.001), and the composite of death from CV causes, myocardial infarction, or stroke by 10% (HR, 0.90; 95% CI, 0.81-1.00; P =.045). 

“Approximately half of heart failure patients die within 5 years of diagnosis, highlighting an urgent unmet need for well-tolerated treatment options that can bring life-saving benefits and reduce the risk of cardiovascular death,” said Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit, AstraZeneca. “The approval of Farxiga in the US not only reinforces AstraZeneca’s commitment to reducing the burden of this complex and life-threatening disease, but will help patients across the full spectrum of heart failure lead healthier lives.”


  1. Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients. News release. AstraZeneca. May 9, 2023.
  2. Solomon S, McMurray JJ, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fractionN Engl J Med. Published online August 27, 2022. doi:10.1056/NEJMoa2206286
  3. Jhund PS, Kondo T, Butt JH, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVERNature Medicine. Published online August 27, 2022.

This article originally appeared on MPR